Medication Guide App

Generic Treximet Availability

Treximet is a brand name of naproxen/sumatriptan, approved by the FDA in the following formulation(s):

TREXIMET (naproxen sodium; sumatriptan succinate - tablet; oral)

  • Manufacturer: SMITHKLINE BEECHAM
    Approval date: April 15, 2008
    Strength(s): 500MG;EQ 85MG BASE [RLD]

Has a generic version of Treximet been approved?

No. There is currently no therapeutically equivalent version of Treximet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Treximet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
    Patent 6,060,499
    Issued: May 9, 2000
    Inventor(s): Plachetka; John R.
    Assignee(s): Pozen, Inc.
    This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
    Patent expiration dates:
    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    Patent 6,586,458
    Issued: July 1, 2003
    Inventor(s): John R.; Plachetka
    Assignee(s): Pozen Inc.
    The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
    Patent expiration dates:
    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Multilayer dosage forms containing NSAIDs and triptans
    Patent 7,332,183
    Issued: February 19, 2008
    Inventor(s): Plachetka; John R. & Kothapalli; Venkata Markandeya & Gilbert; Donna L.
    Assignee(s): Pozen Inc.
    The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.
    Patent expiration dates:
    • October 2, 2025
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
    Patent 8,022,095
    Issued: September 20, 2011
    Inventor(s): Plachetka; John R.
    Assignee(s): Pozen, Inc.
    The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.
    Patent expiration dates:
    • August 14, 2017
      ✓ 
      Patent use: TREATMENT OF MIGRAINE
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web1)